Novo Nordisk is considering options ahead of key heart safety data for its diabetes drug Victoza and could run a further clinical study if necessary, the Danish company’s research head said on Wednesday. The outcome of Novo’s current cardiovascular trial, known as LEADER, has become critical following the unprecedented success of Eli Lilly and Boehringer Ingelheim’s […]

Botox-maker Allergan Plc, which is in talks to be bought by Pfizer Inc, reported a better-than-expected quarterly profit on strong sales of high-margin branded drugs, its biggest business. Shares of Allergan, created from the merger of Actavis and Allergan, rose 1.4 percent to $313.50 in premarket trading on Wednesday. The Actavis-Allergan merger brought signature drugs […]

New York-based Bristol-Myers Squibb Company (BMY) announced today that it is acquiring Chapel Hill, N.C.-based Cardioxyl for up to about $2.07 billion.   Cardioxyl focuses on developing drugs for cardiovascular diseases. As part of the deal, Bristol-Myers Squib picks up the company’s lead asset, CXL-1427, a novel nitroxyl (HNO) donor (prodrug) that is currently in […]

As drugmakers including Novartis, Juno Therapeutics and Kite Pharma race to launch what may be the most effective treatments ever seen for leukemia and other blood cancers, they are grappling with how to make them widely available in a reliable and cost-efficient way.   The new therapies, known as CAR T cells, are made by […]

Novato, Calif.-based Ultragenyx Pharmaceutical Inc. (RARE), announced today that it has inked a research and collaboration deal with San Diego-based Arcturus Therapeutics, Inc.   The two companies will work to identify and develop messenger RNA (mRNA) therapeutics for rare disease targets utilizing Arcturus’ UNA Oligomer chemistry and LUNAR nanoparticle delivery program. Ultragenyx will pay Arcturus […]

Amgen Inc (AMGN.O) on Wednesday reported much higher-than-expected third-quarter profit, helped by a 30-percent spike in revenue from the rheumatoid arthritis drug Enbrel due to price increases and inventory stocking. The world’s largest biotechnology company raised its full-year earnings forecast on the back of the strong quarter, and issued its first 2016 projections for adjusted […]

U.S. health regulators on Tuesday approved Amgen Inc’s novel cancer immunotherapy for injection into melanoma lesions and lymph nodes of patients with the deadliest form of skin cancer that returns after initial surgery. The drug, to be sold under the brand name Imlygic, is an engineered version of a herpes virus that kills cancer cells […]

An experimental heart drug from GlaxoSmithKline failed to work as hoped in the first part of a large clinical trial, the company said on Tuesday, dealing a blow to its pipeline of new medicines.   Losmapimod was being assessed as a treatment to reduce the risk of further cardiovascular problems after heart attacks, but it […]

The U.S. Food and Drug Administration on Thursday approved Merrimack Pharmaceutical Inc’s pancreatic cancer drug, Onivyde, with a severe safety warning. The company’s shares fell as much as 28 percent to a 13-month low of $7.27 in afternoon trade before halving the losses. Onivyde, in combination with chemotherapy treatments 5-fluorouracil and leucovorin, aims to treat […]

The U.S. Food and Drug Administration approved Relypsa Inc’s drug to treat potentially fatal levels of potassium in patients with chronic kidney disease or heart problems. The drug, Veltassa, is designed to treat hyperkalemia, a chronic condition characterized by excessive potassium levels in the blood that could lead to dangerous changes in heart rhythm. Relypsa’s […]